PT-141 (Bremelanotide) is a synthetic peptide melanocortin agonist originally derived from Melanotan II. Unlike PDE5 inhibitors (Viagra, Cialis), PT-141 works through the central nervous system to enhance sexual desire and arousal in both men and women.
PT-141 activates melanocortin receptors (MC3R and MC4R) in the hypothalamus, directly stimulating the dopaminergic pathways involved in sexual arousal. This central mechanism of action means it addresses desire and motivation, not just the physical vascular response, making it effective for both male erectile dysfunction and female hypoactive sexual desire disorder.
PT-141 typically produces noticeable effects within 45–90 minutes of subcutaneous administration. Users report enhanced libido, arousal, and sexual satisfaction. The FDA-approved version (Vyleesi) is licensed for premenopausal women with HSDD.